Respiratory Diseases

AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year. The drug, Benralizumab, is a new biological treatment for people with severe asthma, and works by targeting eosinophils that cause inflammation in the lungs of some patients with severe, uncontrolled asthma. Benralizumab is Astra’s first biologic respiratory medication to pass Phase III trials, with the company hoping to file with US regulators before the end of this year. However, Benralizumab does not have first-mover advantage as GlaxoSmithKline and Teva Pharmaceuticals already have two eosinophil-targeting as...